Physician profile
Dan Q Tran
NPI 1518185305
$1,210.66
in general payments reported to CMS, 2019-2025
11 companies · $49.15 in 2025
The $49.15 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2020: $237 · 2021: $396 · 2022: $65.56 · 2023: $194 · 2024: $53.00 · 2025: $49.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $296.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $523.68 | 2020-2024 | Xarelto |
| Abbott Laboratories | $215.81 | 2019 | |
| Ironwood Pharmaceuticals, INC | $198.73 | 2022-2024 | Linzess |
| Sun Pharmaceutical Industries INC. | $84.03 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.53 | 2022-2023 | |
| Mallinckrodt Hospital Products INC. | $25.96 | 2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $23.19 | 2025 | Breztri |
| Lilly USA, LLC | $19.43 | 2023 | Jardiance |
| Eisai INC. | $17.60 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.58 | 2021 | |
| Allergan, INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.